GH Research plc has provided an update on its clinical development pipeline, highlighting progress with its lead product candidate, GH001, for the treatment of treatment-resistant depression (TRD). The company reported completion of a randomized, double-blind, placebo-controlled Phase 2b trial, which showed a statistically significant reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores for GH001 compared to placebo at Day 8, with a mean difference of -15.5 (_P_ <0.0001) and an effect size of Cohen’s _d_ = -2.0. GH001 is being developed for inhalation administration and is set to advance into a pivotal global Phase 3 program in 2026. Additional pipeline updates include completed studies in bipolar II disorder with current major depressive episodes and postpartum depression. As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities of $293.9 million. You can access the full presentation through the link below. [https://clinicaltrials.gov/study/NCT05800860](https://clinicaltrials.gov/study/NCT05800860)

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on January 05, 2026, and is solely responsible for the information contained therein.